Skip to Content
NCI Experimental Therapeutics Program (NExT)



Renewal Announcement

The National Cancer Institute is pleased to announce the renewal of the Chemical Biology Consortium (CBC), the discovery engine for the NCI Experimental Therapeutics (NExT) Program. Established in 2009, NCI’s CBC is a flexible network of scientists working to discover drug candidates for novel and challenging targets for cancer treatment.

In April 2016, the CBC network was expanded from 12 to 22 centers, including 7 Dedicated Centers and 15 Specialized Centers, with world-class expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. The Dedicated Centers (colored blue below) support the advancement of NExT discovery projects through all discovery stages and provide scientific leadership for the Consortium. The Specialized Centers (colored pink below) provide uniquely focused technologies that facilitate the successful progression of NExT discovery projects at specific discovery stages.

The NExT CBC program is seeking partnerships with academic investigators and clinicians who have a passion for translational research. To submit an application, please visit How to Apply.

Map showing the Dedicated Centers of the Chemical Biology Consortium (CBC)

Who is the NExT Program for?

Domestic and international researchers in academia, nonprofit, government & industry

What does the NExT Program do?

NExT is NOT a grant mechanism. Instead, NExT provides resources for projects focused on developing therapies for unmet needs that are not adequately addressed by the private sector.